Table 1.
Study participant characteristics at baseline (N = 125) among COPD patients (2012–2014).
| N = 125 participants (342 assessments) | Mean (SD) or % |
|---|---|
| Patient characteristics at study entry | |
| Age, yr | 73.3 (8.7) |
| Male sex, % | 98.1 |
| Race, % | |
| White | 90.8 |
| Non-White | 9.2 |
| BMI, Kg/m2 | 30.1 (5.8) |
| Height | 171.8 (7.0) |
| Pack-years (Former smokers, n = 119) | 60.5 (41.8) |
| Heart Disease,% | 53.4 |
| Diabetes,% | 25.1 |
| Education, yr | 13.1 (2.2) |
| Patient characteristics from the 342 assessments | |
| Pre-Bronchodilator | |
| FVC (L) | 3.32 (0.80) |
| %-predicted FVC | 87.0 (19.4) |
| FEV1(L) | 1.8 (0.6) |
| %-predicted FEV1 | 66.5 (21.3) |
| FEV1/FVC (L) | 0.5 (0.1) |
| Post-Bronchodilator | |
| FVC (L) | 3.46 (0.81) |
| %-predicted FVC | 90.0 (19.9) |
| FEV1(L) | 1.93 (0.61) |
| %-predicted FEV1 | 69.7 (21.5) |
| FEV1/FVC (L) | 0.5 (0.1) |
| Medications, % | |
| Long-acting bronchodilator | |
| Long-acting muscarinic antagonists | 65.2 |
| Long-acting β2 agonists | 65.4 |
| Theophylline | 1.1 |
| Short-acting bronchodilator | 75.4 |
| Inhaled steroids | 75.2 |
| Cold or other respiratory illness in the past 2 weeks | 14.4 |
| Other environmental characteristics | |
| Season (%) | |
| Winter (Dec - Feb) | 21.7 |
| Spring (Mar - May) | 25.4 |
| Summer (Jun - Aug) | 25.9 |
| Fall (Sep - Nov) | 26.9 |
| Time indoors at home on weekdays (h) | 17.1 (3.9) |
| Time indoors at home on weekends (h) | 17.1 (4.7) |
| Days of indoor home sampling (N) | 7.6 (0.7) |